Table 1.
Phenotypic resistance at week 96 by antiretroviral drug
| Drug | cNVP (n = 17) |
cABC (n = 35) |
P valueb | ||
|---|---|---|---|---|---|
| n (%) below biological cut-off | relative change in FCa (95% CI) | n (%) below biological cut-off | relative change in FCa (95% CI) | ||
| Zidovudine | 10 (59) | 2.58 (1.73, 3.86) | 18 (51) | 3.88 (2.86, 5.25) | 0.27 |
| Abacavir | 11 (65) | 2.09 (1.45, 3.00) | 17 (49) | 3.36 (2.51, 4.51) | 0.06 |
| Didanosine | 16 (94) | 1.27 (0.87, 1.83) | 31 (89) | 1.76 (1.33, 2.31) | 0.14 |
| Tenofovir DF | 16 (94) | 1.00 (0.72, 1.38) | 31 (89) | 1.63 (1.29, 2.06) | 0.02 |
| Nevirapine | 1 (6) | 29.46 (19.49, 44.54) | 31 (89) | 1.46 (1.10, 1.95) | <0.001 |
| Efavirenz | 4 (24) | 32.47 (18.14, 58.12) | 35 (100) | 0.84 (0.67, 1.05) | <0.001 |
| Etravirine | 8 (47) | 3.44 (2.17, 5.47) | 35 (100) | 0.70 (0.56, 0.89) | <0.001 |
aRatio of geometric mean FC (relative to wild-type) at week 96 compared with geometric mean FC at week 0.
bt-test for 96 week difference in mean FC between treatment arms.